|
Volumn 3, Issue 1, 2003, Pages 87-88
|
To the Editor: [1]
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BONE MORPHOGENETIC PROTEIN;
RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;
RECOMBINANT OSTEOGENIC PROTEIN 1;
BMP2 PROTEIN, HUMAN;
BONE MORPHOGENETIC PROTEIN 2;
OSTEOGENIC PROTEIN 1;
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN 2;
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2;
RECOMBINANT PROTEIN;
TRANSFORMING GROWTH FACTOR BETA;
BONE DEMINERALIZATION;
BONE GRAFT;
BONE MATRIX;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG MECHANISM;
FRACTURE HEALING;
FRACTURE NONUNION;
HUMAN;
INTERMETHOD COMPARISON;
LETTER;
NONHUMAN;
OSSIFICATION;
OSTEOLYSIS;
OSTEOSARCOMA;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
RISK ASSESSMENT;
SPINE FUSION;
ANIMAL;
BONE DEVELOPMENT;
PHYSIOLOGY;
ANIMALS;
BONE MORPHOGENETIC PROTEINS;
HUMANS;
OSTEOGENESIS;
RECOMBINANT PROTEINS;
TRANSFORMING GROWTH FACTOR BETA;
|
EID: 1542473021
PISSN: 15299430
EISSN: None
Source Type: Journal
DOI: 10.1016/S1529-9430(02)00573-9 Document Type: Letter |
Times cited : (3)
|
References (9)
|